| Cancer |
Public Current Cancer Trials
Bone Metastases
(Observational)
A prospective observational Multicenter Cohort Study to Assess the Incident of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment.
BRAIN
N0574 XRT ONLY
Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients with One to Three Cerebral Metastases.
RTOG 0834 - (Anaplastic Glioma)
Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic Glioma: The Catnon Intergroup Trial.
CTSU A221101: The Use of Armodafinil (Nuvigil) to Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiform: A Randomized, Novel Adaptive Design Study.
BREAST
SCCA 6628
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed by Bevacizumab and Erlotinib in Treating Patients With Metastatic Breast Cancer
Please Contact:
Christine Goetz, BA, CCRC
253-403-7193;
Pager 253-305-1189
NSABP B-43
A Phase III Clinical Trial Comparing Trastuzumab given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In situ Resected by Lumpectomy.
HLMCC 0806
(Adjuvant OR Neoadjuvant)
Phase II placebo-controlled trial of lisinopril and Coreg to reduce cardiotoxicity in patients with breast cancer receiving (neo) adjuvant chemotherapy with trastuzumab (Herceptin).
S1105
Randomized Trial of Text-Messaging Intervention to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in women with Early Stage Breast Cancer.
PRESENT-Vaccine Trial
Prevention of Recurrence in Early Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVaxTM Treatment.
E2108: A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patents with Metastatic Breast Cancer
BREAST - Cont.
SWOG 1007
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.
NSABP B-47
A Randomized Phase III Trial of Adjuvant Therapy Comparing
Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer.
NSABP B-49
A Phsae III Clinical trial comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer.
PRESENT-Vaccine TrialPrevention of Recurrence in Early Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVaxTM Treatment. Contact:
Christine Goetz, BA, CCR
Phone: 253-403-7193
Pager: 253-305-1189
Cancer Related Fatigue
GASTROINTESTINAL
CALGB 80702
A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer.
NSABP P-5
(Polyp Prevention Trial)
Statin Polyp prevention Trial in Patients with Resected Colon Cancer.
Click for Protocol Summary
Contact:
Christine Goetz, BA, CCRC
Phone: 253-403-7193
Pager: 253-305-1189
RTOG 0848
A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.
RTOG 1010
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
S1201
A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/metastatic Esophageal, Gastric, or Gastroesophageal Junction (GEJ) Cancer.
GENITOURINARY
SWOG 1014
Abiraterone Acetate Treatment for Prostate Cancer patients with a PSA of More than Four Following Initial Androgen Deprivation Therapy, Phase II.
RTOG 0815
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer.
RTOG 0534
A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy.
CALGB 90203
Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer.
CALGB 70807
The Men's Eating and Living (MEAL) Study: A Randomized Trial of diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance.
Click for Protocol Summary
7048-RAD1
Phase II Trial of Radiation with Androgen Deprivation: Abiraterone Acetate, Prednisone and LHRH Agonist Prior to and Concurrent with Radiation Therapy.
SWOG 0931
Everest: Everolimus for Renal Cancer Ensuring Surgical Therapy, a Phase III Study
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy.
Click for Protocol Summary
CALGB 90601
A randomized double-blinded Phase III study comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in patients with advanced transitional cell carcinoma (TCC).
GYNECOLOGIC
RTOG 0724
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy.
Click for Protocol Summary
Ovarian
GOG 0262
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer.Click for
Protocol Summary
Contact:
Christine Goetz:
253-403-7193;
Pager 253-305-1189
GOG 213
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC#704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian,Peritoneal Primary and Fallopian Tube Cancer.
Click for Protocol Summary
Contact:
Christine Goetz, BA, CCRC
253-403-7193;
Pager 253-305-1189
MULTICARE CLINIC ONLY
GOG 212
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or XyotaxTM (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy.
Click for Protocol Summary
Contact:
Christine Goetz:
253-403-7193;
Pager 253-305-1189
MULTICARE CLINIC ONLY
GOG 0186J - Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
A randomized phase IIB evaluation of weekly Paclitaxel plus PazopanIB versus weekly Pacliataxel plus placebo in the treatment of persistent or recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carconoma.
Click for Protocol Summary
Contact:
Christine Goetz, BA, CCRC
Phone: 253-403-7193
Pager: 253-305-1189
GOG 0261
(CIRB): A Randomized Phase III Trial of Paclitaxel Plus Carboplatin versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naïve Patients with Newly Diagnosed Stage I-IV Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal tumors) of the Uterus or Ovary.
Contact:
Christine Goetz, BA, CCRC
253-403-7193;
Pager 253-305-1189
GOG 0258
A Randomized Phase III Trial of Cisplatin and tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carconoma.
Please Contact:Christine Goetz, BA, CCRC
253-403-7193;
Pager 253-305-1189
HEAD AND NECK
LIVER
CALGB 80802
Phase III Randomized Study of Sorafenib plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC).
Click for Protocol Summary
E1208
A Phase III Randomized, Double Blind Trial of Chemoembolization with or without Sorefenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion.
Click for Protocol Summary
LUNG
CALGB 140503
A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<2 Cm) Peripheral Non-Small Cell Lung Cancer.
ACCURAY-ACCL001.1
(Cyberknife)
A prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer.
Contact:
Samantha Elliott
253-403-2319
ECOG 5508
Randomized Phase III Study of Maintenance Therapy with Bevacizumab Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advance Non-Squamous NSCLC.
SWOG 0819
A Randomized Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without concurrent Cetuximab in patients with advanced non-small cell lung cancer.
ECOG 1505
A Phase III Randomized Trial of Adjuvant chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (>4 cm) IIIA Non-Small Lung Cancer.
C30801
A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer.
LYMPHOCYTIC LEUKEMIA
A Phase I/II Study of Fludarabine, Cyclophosphamide Rituximab, and Vorinostat Followed by Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
Contact:
253-403-7193;
Pager 253-305-1189
MULTICARE CLINIC ONLY
PSOC 2301
A Phase II Study of Bexxar Consolidation in Patients with B-Cell Chronic Lymphocytic Leukemia Following Fludarabine and Rituximab Chemotherapy.
Contact:
Christine Goetz, BA, CCRC
253-403-7193;
Pager 253-305-1189
MULTICARE CLINIC ONLY
LYMPHOMA
S1106-Arm 1 closed
A Randomized Phase II Trial of R-HCVAD/MTX/Ara-C Induction Followed by Consolidation with an Autologous Stem Cell Transplant vs. R-Bendamustine Induction Followed by Consolidation with an Autologous Stem Cell Transplant for Patients < 65 Years of Age with Previously Untreated Mantle Cell Lymphoma.
MELANOMA
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-risk Melanoma.
MULTIPLE MYELOMA
Radnomized Phase III Trial of lenalidomide versus observation alone in patients with Asymptomatic high-risk smoldering multiple myeloma.